Zytoprotec Overview

  • Founded
  • 2007
  • Status
  • Private
  • Latest Deal Type
  • Series A2
  • Latest Deal Amount
  • $9M
Latest Deal Amount
  • Investors
  • 1

Zytoprotec General Information


Developer of a biotechnology platform intended to develop drugs using a novel therapeutic approach. The company's platform develops a product that is based on a protected cytoprotective compound that helps in restoring the protective mechanism of cells, enabling physicians to improve the quality of life and the survival of patients.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Outcome Management (Healthcare)
Other Healthcare Technology Systems
Primary Office
  • Mariannengasse 28/2
  • Vienna, 1090
  • Austria
+43 01 0000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Zytoprotec Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC (Series A2) 01-Jan-2016 $9M 000.00 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A) 29-Jan-2013 00.000 000.00 Completed Clinical Trials - Phase 2
1. Early Stage VC $8.91M $8.91M Completed Startup
To view Zytoprotec’s complete valuation and funding history, request access »

Zytoprotec Executive Team (7)

Name Title Board Seat Contact Info
Bernd Seibel Managing Director and Board Member
Bernhard Zinner Managing Director
Christoph Aufricht Co-Founder and Chief Scientific Officer
Karl Hengstberger Chairman
You’re viewing 4 of 7 executive team members. Get the full list »

Zytoprotec Board Members (8)

Name Representing Role Since
Bernd Seibel Zytoprotec Managing Director and Board Member 000 0000
Jason Slingsby Self Board Member 000 0000
Jörg Vienken Ph.D Zytoprotec Board Member 000 0000
Karl Hengstberger Zytoprotec Chairman 000 0000
Norbert Riedel Ph.D Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

Zytoprotec Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Baxter Ventures Corporate Venture Capital Minority 000 0000 000000 0
To view Zytoprotec’s complete investors history, request access »